Neurosurgical FOCUS · 2000 · 21 citations · 28 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCancer VaccinesImmunogenicity Of Gene TherapiesImmunotherapy For Brain TumorsTherapeutic VaccinesViral VaccinesGlioblastoma ImmunologyGlioblastoma ImmunotherapyImmunological ResponseIntratumoral AdministrationTherapeutic Cancer ImmunizationTherapeutic Efficacy AssessmentTherapeutic Vaccine EfficacyViral Vector Cancer Vaccines
OBJECT: The authors investigated immunogene therapy for malignant glioma to determine whether its therapeutic efficacy could be improved. METHODS: Four groups of 203-glioma-bearing mice were treated with injections of phosphate-buffered saline, Semliki Forest virus (SFV)-LacZ, retrovirus vector DFG-interleukin (IL)-12, and SFV-IL12, respectively. The results indicated that therapeutic immunization with SFV-IL12 prolonged the survival of mice with established tumors. Semliki Forest virus induces apoptotic death to glioma cells, which facilitates the uptake of apoptotic cells by dendritic cells, providing a potential mechanism for enhanced immunogenicity. CONCLUSIONS: Immunogene therapy with IL-12 via SFV may be an excellent candidate for the development of new cancer vaccines.
28
Requirement for V <sub>α</sub> 14 NKT Cells in IL-12-Mediated Rejection of Tumors
Junqing Cui, Tahiro Shin, Tetsu Kawano et al. · Science · 1997 · 1.2K citations